| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Muhammad Wasif Saif, Alicia Romano, Melissa H Smith, Rachana Patel, Valerie Relia. Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect. Cancer medicine journal. vol 3. issue 2. 2020-09-28. PMID:32405630. |
somatostatin analogues (ssas) are used to treat gastroenteropancreatic neuroendocrine tumors (gep-nets) and acromegaly. |
2020-09-28 |
2023-08-13 |
Not clear |
| Nikolaos Kyriakakis, Khyatisha Seejore, Ahmed Hanafy, Robert D Murra. Management of persistent acromegaly following primary therapy: The current landscape in the UK. Endocrinology, diabetes & metabolism. vol 3. issue 3. 2020-09-28. PMID:32704572. |
in this article, we discuss options for the management of persistent acromegaly following initial surgery and somatostatin analogue therapy, and explore earlier use of dopaminergics and conservative management. |
2020-09-28 |
2023-08-13 |
Not clear |
| Maria Caroline Alves Coelho, Marina Lipkin Vasquez, Luiz Eduardo Wildemberg, Mari C Vázquez-Borrego, Luciana Bitana, Aline Helen da Silva Camacho, Débora Silva, Liana Lumi Ogino, Nina Ventura, Rafael Sánchez-Sánchez, Leila Chimelli, Leandro Kasuki, Raul M Luque, Mônica R Gadelh. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Scientific reports. vol 9. issue 1. 2020-08-20. PMID:30718563. |
clinical significance of filamin a in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. |
2020-08-20 |
2023-08-13 |
Not clear |
| Eva Venegas-Moreno, Alvaro Flores-Martinez, Elena Dios, Mari C Vazquez-Borrego, Alejandro Ibañez-Costa, Ainara Madrazo-Atutxa, Miguel A Japón, Justo P Castaño, Raúl M Luque, David A Cano, Alfonso Soto-Moren. E-cadherin expression is associated with somatostatin analogue response in acromegaly. Journal of cellular and molecular medicine. vol 23. issue 5. 2020-07-24. PMID:30843342. |
e-cadherin expression is associated with somatostatin analogue response in acromegaly. |
2020-07-24 |
2023-08-13 |
Not clear |
| Eva Venegas-Moreno, Alvaro Flores-Martinez, Elena Dios, Mari C Vazquez-Borrego, Alejandro Ibañez-Costa, Ainara Madrazo-Atutxa, Miguel A Japón, Justo P Castaño, Raúl M Luque, David A Cano, Alfonso Soto-Moren. E-cadherin expression is associated with somatostatin analogue response in acromegaly. Journal of cellular and molecular medicine. vol 23. issue 5. 2020-07-24. PMID:30843342. |
somatostatin analogues (ssas) represent the primary medical therapy for acromegaly and are currently used as first-line treatment or as second-line therapy after unsuccessful pituitary surgery. |
2020-07-24 |
2023-08-13 |
Not clear |
| Tiziana Feola, Alessia Cozzolino, Ilaria Simonelli, Emilia Sbardella, Carlotta Pozza, Elisa Giannetta, Daniele Gianfrilli, Patrizio Pasqualetti, Andrea Lenzi, Andrea M Isidor. Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies. The Journal of clinical endocrinology and metabolism. vol 104. issue 7. 2020-06-01. PMID:30869797. |
pegvisomant (peg) in monotherapy or combined with somatostatin analogs (ssas) is used to control acromegaly, improving metabolism. |
2020-06-01 |
2023-08-13 |
Not clear |
| Maria Fleseriu, Leon Fogelfeld, Murray B Gordon, Jill Sisco, Hilary H Colwell, William H Ludlam, Asi Haviv, Susan D Mathia. Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary. vol 22. issue 6. 2020-05-18. PMID:31522359. |
somatostatin analogs (ssas) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections. |
2020-05-18 |
2023-08-13 |
Not clear |
| Eva C Coopmans, Joppe J Schneiders, Nour El-Sayed, Nicole S Erler, Leo J Hofland, Aart-Jan van der Lely, Patrick Petrossians, Julia Potorac, Ammar Muhammad, Sebastian J C M M Negger. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. European journal of endocrinology. vol 182. issue 6. 2020-05-14. PMID:32375119. |
t2-signal intensity, sstr expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. |
2020-05-14 |
2023-08-13 |
Not clear |
| Eva C Coopmans, Ammar Muhammad, Aart J van der Lely, Joseph A M J L Janssen, Sebastian J C M M Negger. How to Position Pasireotide LAR Treatment in Acromegaly. The Journal of clinical endocrinology and metabolism. vol 104. issue 6. 2020-05-05. PMID:30608534. |
pasireotide long-acting release (lar) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide lar is considered the second-line medical treatment for acromegaly. |
2020-05-05 |
2023-08-13 |
Not clear |
| Aart J van der Lely, Emmanuelle Kuhn, Ammar Muhammad, Eva C Coopmans, Sebastian J Neggers, Philippe Chanso. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly. European journal of endocrinology. vol 182. issue 6. 2020-05-04. PMID:32234975. |
pegvisomant and not somatostatin receptor ligands (srls) is first-line medical therapy for acromegaly. |
2020-05-04 |
2023-08-13 |
Not clear |
| Aart J van der Lely, Emmanuelle Kuhn, Ammar Muhammad, Eva C Coopmans, Sebastian J Neggers, Philippe Chanso. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly. European journal of endocrinology. vol 182. issue 6. 2020-05-04. PMID:32234975. |
current guidelines recommend the use of long-acting somatostatin receptor ligands (srls) first when surgery fails to correct gh/igf-i hypersecretion in patients with acromegaly. |
2020-05-04 |
2023-08-13 |
Not clear |
| Federico Gatto, Claudia Campana, Francesco Cocchiara, Giuliana Corica, Manuela Albertelli, Mara Boschetti, Gianluigi Zona, Diego Criminelli, Massimo Giusti, Diego Feron. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Reviews in endocrine & metabolic disorders. vol 20. issue 3. 2020-04-20. PMID:31342434. |
somatostatin receptor ligands, dopamine agonists and a gh receptor antagonist are currently available for medical therapy of acromegaly. |
2020-04-20 |
2023-08-13 |
Not clear |
| Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong Su Moon, Dong Jun Lim, Dong Yeob Shin, Se Hwa Kim, Min Jeong Kwon, Ha Young Kim, Jin Hwa Kim, Dong Sun Kim, Chong Hwa Ki. Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement. Endocrinology and metabolism (Seoul, Korea). vol 34. issue 1. 2020-04-06. PMID:30912339. |
medical treatment with somatostatin analogues in acromegaly: position statement. |
2020-04-06 |
2023-08-13 |
Not clear |
| Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong Su Moon, Dong Jun Lim, Dong Yeob Shin, Se Hwa Kim, Min Jeong Kwon, Ha Young Kim, Jin Hwa Kim, Dong Sun Kim, Chong Hwa Ki. Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement. Endocrinology and metabolism (Seoul, Korea). vol 34. issue 1. 2020-04-06. PMID:30912339. |
in 2017, the kes committee of health insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. |
2020-04-06 |
2023-08-13 |
Not clear |
| Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong Su Moon, Dong Jun Lim, Dong Yeob Shin, Se Hwa Kim, Min Jeong Kwon, Ha Young Kim, Jin Hwa Kim, Dong Sun Kim, Chong Hwa Ki. Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement. Endocrinology and metabolism (Seoul, Korea). vol 34. issue 1. 2020-04-06. PMID:30912339. |
this position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. |
2020-04-06 |
2023-08-13 |
Not clear |
| Mônica Gadelha, Marie Bex, Annamaria Colao, Elier Mitsael Pedroza García, Catalina Poiana, Marisela Jimenez-Sanchez, Serkan Yener, Rishav Mukherjee, Amy Bartalotta, Ricardo Maamari, Gérald Ravero. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. Frontiers in endocrinology. vol 10. 2020-03-05. PMID:32117045. |
evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. |
2020-03-05 |
2023-08-13 |
Not clear |
| Emine Sebnem Durmaz, Burak Kocak, Pinar Kadioglu, Nil Comunoglu, Mustafa Onur Ulu, Naci Kocer, Civan Islak, Osman Kizilkili. Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Acromegaly Patients. Turkish neurosurgery. vol 29. issue 6. 2020-02-17. PMID:30900736. |
added value of dynamic contrast-enhanced magnetic resonance imaging in predicting response to somatostatin analogs in acromegaly patients. |
2020-02-17 |
2023-08-13 |
Not clear |
| Emine Sebnem Durmaz, Burak Kocak, Pinar Kadioglu, Nil Comunoglu, Mustafa Onur Ulu, Naci Kocer, Civan Islak, Osman Kizilkili. Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Acromegaly Patients. Turkish neurosurgery. vol 29. issue 6. 2020-02-17. PMID:30900736. |
to investigate the added value of dynamic contrast-enhanced magnetic resonance imaging (dce-mri) sequences in predicting somatostatin analog (ssa) responses in patients with acromegaly. |
2020-02-17 |
2023-08-13 |
Not clear |
| Annamaria Colao, Wojciech Zgliczyński, Jan Komorowski, Beata Kos-Kudła, Antoine Tabarin, Veronique Kerlan, Francesco M Minuto, Carla Scaroni, Marek Bolanowsk. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynologia Polska. vol 70. issue 4. 2020-02-04. PMID:31274183. |
is a potent, synthetic somatostatin analogue (ssa) that requires less frequent dosing and offers quality of life (qol) benefits in acromegaly patients compared to its shorter-acting predecessor. |
2020-02-04 |
2023-08-13 |
Not clear |
| Ozge Polat Korkmaz, Mert Gurcan, Fatma Eda Nuhoglu Kantarci, Ozlem Haliloglu, Hande Mefkure Ozkaya, Serdar Sahin, Meryem Merve Oren, Necmettin Tanriover, Nurperi Gazioglu, Pinar Kadiogl. The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly. Pituitary. vol 22. issue 4. 2020-01-13. PMID:31098838. |
the effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly. |
2020-01-13 |
2023-08-13 |
Not clear |